A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA.
Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of death by 60% in phase 3 trials. Patients who received the medication in trials lived 13.2 months, compared with those on chemotherapy, who survived 6.7 months.
The drug is approved for adults with metastatic pancreatic adenocarcinoma (PDAC). Pancreatic cancer is the third-leading cause of cancer death in the U.S. behind lung and colorectal cancers, according to the American Cancer Society.
However, the treatment comes with a steep list price of roughly $477,000 a year. What patients actually pay will depend on their insurance coverage and eligibility for financial assistance.
Double the cost of the top-selling cancer drug
In a filing with the Securities and Exchange Commission, Revolution Medicines said Rasonque has a wholesale acquisition cost, or list price before insurance discounts and rebates, of approximately $39,800 for a 30-day supply at the recommended daily dose, or about $477,000 per year.
Trade publication BioPharma Dive noted the figure is more than double the list price of Merck’s Keytruda, the top-selling cancer medication.
The list price isn’t necessarily what patients will pay, however. On the investor conference call held to announce the FDA approval on Wednesday, Revolution Medicines CFO Jack Anders said some eligible patients would be covered by Medicare Part D. Additional government discounts would lower the price by an estimated 20% to 30%.
The pharmaceutical company’s (ON)Path program says it can help patients “find the best programs and resources to help you or your loved one start on treatment as soon as possible.”
Revolution Medicines’ investor call announcing Rasonque included a presentation stating that the drug could be purchased with “as little as $0 co-pay for eligible commercially insured patients.”
A major advance in treating pancreatic cancer
Daraxonrasib is not a cure for pancreatic cancer but is a life-extending option for patients who have undergone chemotherapy with limited success.
The FDA approved the drug 35 days after accepting Revolution Medicines’ application, citing it as a “critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer.”
The FDA noted the most common side effects as rash, diarrhea, inflammation of the mouth’s mucous membranes, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.
Anna Berkenblit, M.D., chief scientific and medical officer for the Pancreatic Cancer Action Network (PanCAN), called the FDA’s approval “the most significant advance we have seen in the fight against pancreatic cancer, a devastating disease. In addition, an oral pill can offer a less burdensome treatment experience than standard intravenous chemotherapy.”
Some 67,000 people are expected to be diagnosed with pancreatic cancer in 2026, according to the American Cancer Society. Because there are often few or no symptoms, most patients learn they have the disease after it has spread, and treatment options are limited.
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
Cutting Two Amino Acids Slowed Prostate Cancer in Mice
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they [...]
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
